Table 2. Treatment outcomes in PCOS and non-PCOS patients.
| Variables | All patients | PCOS | Non-PCOS | p-value | |
|---|---|---|---|---|---|
| No. of patient | 285 | 103 | 182 | - | |
| 16-wk CR rate* | |||||
| All | 28.2 | 18.4 | 33.8 | 0.006 | |
| AEH | 31.3 | 21.4 | 36.3 | 0.030 | |
| EEC | 19.9 | 12.1 | 26.0 | 0.134 | |
| 32-wk CR rate* | |||||
| All | 62.2 | 61.2 | 62.7 | 0.256 | |
| AEH | 65.0 | 67.1 | 63.7 | 0.633 | |
| EEC | 54.6 | 48.5 | 59.4 | 0.257 | |
| 24-mo CR rate* | |||||
| All | 97.6 | 100.0 | 95.7 | 0.854 | |
| AEH | 97.1 | 100.0 | 95.6 | 0.930 | |
| EEC | 97.7 | 100.0 | 94.8 | 0.839 | |
| Median treatment duration to CR (mo)† | |||||
| All | 6.5 (1.0–28.0) | 7.0 (1.0–21.9) | 5.4 (1.0–28.0) | 0.006 | |
| AEH | 5.8 (1.0–19.2) | 6.6 (1.0–18.5) | 4.9 (1.0–19.2) | 0.037 | |
| EEC | 7.1 (1.0–28.0) | 7.9 (1.0–21.9) | 6.9 (1.0–28.0) | 0.133 | |
| 24-mo recurrence rate* | |||||
| All | 21.9 | 27.5 | 19.3 | 0.383 | |
| AEH | 17.1 | 24.0 | 14.0 | 0.388 | |
| EEC | 124.0 | 36.1 | 36.5 | 0.863 | |
| Median duration to recurrence (mo)‡ | |||||
| All | 14.3 (4.4–34.0) | 9.6 (4.9–27.1) | 17.6 (4.4–34.0) | 0.040 | |
| AEH | 19.8 (6.1–34.0) | 12.5 (6.1–27.1) | 23.8 (9.1–34.0) | 0.056 | |
| EEC | 10.0 (4.4–17.6) | 8.3 (4.9–14.1) | 11.0 (4.4–17.6) | 0.394 | |
| Pregnancy rate§ | |||||
| All | 48.0 (41/84) | 55.2 (16/29) | 45.5 (25/55) | 0.397 | |
| AEH | 54.4 (31/57) | 63.6 (14/22) | 48.6 (17/35) | 0.266 | |
| EEC | 37.0 (10/27) | 28.6 (2/7) | 40.0 (8/20) | 0.678 | |
| Live birth rate∥ | |||||
| All | 53.7 (22/41) | 56.3 (9/16) | 52.0 (13/25) | 0.790 | |
| AEH | 51.6 (16/31) | 57.1 (8/14) | 47.0 (8/17) | 0.576 | |
| EEC | 60.0 (6/10) | 50.0 (1/2) | 62.5 (5/8) | 1.000 | |
Data are shown as % (number) and median (range). p-value: comparison between PCOS and non-PCOS group.
AEH, atypical endometrial hyperplasia; CR, complete response; EEC, endometrioid endometrial cancer; PCOS, polycystic ovary syndrome.
*The 16-week, 32-week and 24-month CR rate and the 24-month recurrence rate were cumulative complete response or recurrence rate at different follow-up points. Cumulative CR/recurrence rates were evaluated with Kaplan-Meier analysis and compared by log-rank test. †The median treatment duration (months) from initiation of conservative treatment to CR. ‡The median duration (months) from achieving CR to recurrence. §Pregnancy rate among patients who attempt to conceive. ∥Live birth rate was calculated among patients who achieved pregnancy.